<HTML xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki  ltr ns-0 ns-subject page-Team_Wageningen_UR_Application_safety"><DIV id="globalWrapper"><DIV id="top-section"><DIV id="p-logo"><A href="/Main_Page" title="Main Page">&quot;
	    </A></DIV><DIV id="menubar" class="left-menu noprint"><UL><LI class="selected"><A href="/Team:Wageningen_UR/Application_safety">Page               </A></LI><LI class="new"><A href="/wiki/index.php?title=Talk:Team:Wageningen_UR/Application_safety&amp;action=edit&amp;redlink=1">Discussion               </A></LI><LI><A href="/wiki/index.php?title=Team:Wageningen_UR/Application_safety&amp;action=edit">View source               </A></LI><LI><A href="/wiki/index.php?title=Team:Wageningen_UR/Application_safety&amp;action=history">History               </A></LI><LI style="color:#808080;cursor:default">teams</LI></UL></DIV><DIV class="right-menu noprint" id="menubar"><UL><LI id="pt-login"><A href="/wiki/index.php?title=Special:UserLogin&amp;returnto=Team:Wageningen_UR/Application_safety" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o">Log in</A></LI></UL></DIV><DIV id="search-controls" class="noprint"><FORM action="/Special:Search" id="searchform"> </FORM></DIV></DIV><DIV id="content"><H1 class="firstHeading">Team:Wageningen UR/Application safety</H1><DIV id="bodyContent"><H3 id="siteSub" class="noprint">From 2012.igem.org</H3><DIV id="gototop"><A href="#thisisthetop" title="Back to top.">Top</A></DIV><DIV id="navContainer"><UL><LI><SPAN><A href="/Team:Wageningen_UR" title="Team:Wageningen UR">Home</A></SPAN></LI><LI><SPAN><A href="/Team:Wageningen_UR/Team" title="Team:Wageningen UR/Team">Team</A></SPAN></LI><LI><A href="/Team:Wageningen_UR/Team" title="Team:Wageningen UR/Team">The Team</A></LI><LI><A href="https://igem.org/Team.cgi?id=883" class="external text" rel="nofollow">Team Registration</A></LI></UL><LI><SPAN><A href="/Team:Wageningen_UR/Project" title="Team:Wageningen UR/Project">Project</A></SPAN></LI><LI><A href="/Team:Wageningen_UR/Project" title="Team:Wageningen UR/Project">1. Introduction</A></LI><LI><A href="/Team:Wageningen_UR/Coil_system" title="Team:Wageningen UR/Coil system">2. PnA System</A></LI><LI class="hassubitems"><SPAN><A href="/Team:Wageningen_UR/VLPs" title="Team:Wageningen UR/VLPs">3. Virus-Like Particles</A></SPAN></LI><LI><A href="/Team:Wageningen_UR/ModifyingtheCCMV" title="Team:Wageningen UR/ModifyingtheCCMV">CCMV</A></LI><LI><A href="/Team:Wageningen_UR/ModifyingtheHepatitisB" title="Team:Wageningen UR/ModifyingtheHepatitisB">HepB</A></LI><LI><A href="/Team:Wageningen_UR/ObtainingthePoleroVLP" title="Team:Wageningen UR/ObtainingthePoleroVLP"><I>Polerovirus</I> Natural BioBrick</A></LI><LI><A href="/Team:Wageningen_UR/OutsideModification" title="Team:Wageningen UR/OutsideModification">4. Outside Modification</A></LI><LI><A href="/Team:Wageningen_UR/InsideModification" title="Team:Wageningen UR/InsideModification">5. Inside Modification</A></LI><LI><A href="/Team:Wageningen_UR/MethodsDetection" title="Team:Wageningen UR/MethodsDetection">6. Detection of VLPs</A></LI><LI><A href="/Team:Wageningen_UR/Applications" title="Team:Wageningen UR/Applications">7. Applications</A></LI><LI><A href="/Team:Wageningen_UR/TheConstructor" title="Team:Wageningen UR/TheConstructor">8. The Constructor</A></LI><LI><A href="/Team:Wageningen_UR/FinalOverview" title="Team:Wageningen UR/FinalOverview">9. Final Overview</A></LI><LI><SPAN><A href="/Team:Wageningen_UR/Human_Practices" title="Team:Wageningen UR/Human Practices">Human Practices</A></SPAN></LI><LI><A href="/Team:Wageningen_UR/Human_Practices" title="Team:Wageningen UR/Human Practices">Human Practices Home</A></LI><LI><A href="/Team:Wageningen_UR/miniSymposium#Online_video_symposium" title="Team:Wageningen UR/miniSymposium">1. Mini Symposium</A></LI><LI><A href="/Team:Wageningen_UR/Visiting_Secondary_School#Visiting_Secondary_Schools" title="Team:Wageningen UR/Visiting Secondary School">2. Visiting Secondary Schools</A></LI><LI class="hassubitems"><A href="/Team:Wageningen_UR/DiscoveryFestival#Discovery_festival" title="Team:Wageningen UR/DiscoveryFestival">3. Discovery Festival</A></LI><LI><A href="/Team:Team:Wageningen_UR/DiscoveryFestival_Communication" title="Team:Team:Wageningen UR/DiscoveryFestival Communication">Communication Science</A></LI><LI><A href="/Team:Wageningen_UR/Stakeholders#Stakeholders" title="Team:Wageningen UR/Stakeholders">4. Stakeholders</A></LI><LI><A href="/Team:Wageningen_UR/CASconference#Synthetic_Biology_CAS-conference_Munich" title="Team:Wageningen UR/CASconference">5. Munich CAS Conference</A></LI><LI><SPAN><A href="/Team:Wageningen_UR/Safety" title="Team:Wageningen UR/Safety">Safety</A></SPAN></LI><LI><A href="/Team:Wageningen_UR/Safety" title="Team:Wageningen UR/Safety">Introduction</A></LI><LI><A href="/Team:Wageningen_UR/General_safety" title="Team:Wageningen UR/General safety">1. General safety</A></LI><LI><A href="/Team:Wageningen_UR/Virus-related_issues" title="Team:Wageningen UR/Virus-related issues">2. Virus-related safety</A></LI><LI><A href="/Team:Wageningen_UR/Regulations" title="Team:Wageningen UR/Regulations">3. Regulations</A></LI><LI><A href="/Team:Wageningen_UR/Possible_Improvements" title="Team:Wageningen UR/Possible Improvements">4. Safety suggestions</A></LI><LI><STRONG class="selflink">5. Safety of applications</STRONG></LI><LI><SPAN><A href="/Team:Wageningen_UR/Modeling" title="Team:Wageningen UR/Modeling">Modeling</A></SPAN></LI><LI><SPAN><A href="/Team:Wageningen_UR/HumanBody" title="Team:Wageningen UR/HumanBody">Human Body Model</A></SPAN></LI><LI><SPAN><A href="/Team:Wageningen_UR/InSilico" title="Team:Wageningen UR/InSilico">Tertiary folding prediction</A></SPAN></LI><LI><SPAN><A href="/Team:Wageningen_UR/FormationModel" title="Team:Wageningen UR/FormationModel">VLP assembly model</A></SPAN></LI><LI><SPAN><A href="/Team:Wageningen_UR/Attributions" title="Team:Wageningen UR/Attributions">Attributions</A></SPAN></LI><LI><SPAN><A href="/Team:Wageningen_UR/Parts" title="Team:Wageningen UR/Parts">Parts</A></SPAN></LI><LI><SPAN><A href="/Team:Wageningen_UR/Notebook" title="Team:Wageningen UR/Notebook">Notebook</A></SPAN></LI><LI><A href="/Team:Wageningen_UR/Journal" title="Team:Wageningen UR/Journal">Journal</A></LI><LI><A href="/Team:Wageningen_UR/Protocol" title="Team:Wageningen UR/Protocol">Protocols</A></LI></DIV><DIV id="contentfooter"><DIV class="fcol"><P>Last year's project: <A href="https://2011.igem.org/Team:Wageningen_UR" class="external text" rel="nofollow">Synchronized Oscillatory System</A></P></DIV><DIV class="fcol"><P><A href="https://igem.org/Main_Page#" class="external text" rel="nofollow">iGEM Home</A></P></DIV><DIV class="fcol"><P><A href="/Team:Wageningen_UR/ContactUs" title="Team:Wageningen UR/ContactUs">Contact Us</A></P></DIV><DIV class="fullfooter"><H4>Our Sponsors:</H4></DIV></DIV><TABLE id="toc" class="toc"><TBODY><TR><TD><DIV id="toctitle"><H2>Contents</H2></DIV><UL><LI class="toclevel-1 tocsection-1"><A href="#Safety_of_medical_application:_A_brief_literature_study"><SPAN class="tocnumber">1</SPAN><SPAN class="toctext">Safety of medical application: A brief literature study</SPAN></A></LI><LI class="toclevel-2 tocsection-2"><A href="#VLPs_in_the_human_body"><SPAN class="tocnumber">1.1</SPAN><SPAN class="toctext">VLPs in the human body</SPAN></A></LI><LI class="toclevel-2 tocsection-3"><A href="#VLP-encapsulated_medicine"><SPAN class="tocnumber">1.2</SPAN><SPAN class="toctext">VLP-encapsulated medicine</SPAN></A></LI><LI class="toclevel-2 tocsection-4"><A href="#References"><SPAN class="tocnumber">1.3</SPAN><SPAN class="toctext">References</SPAN></A></LI><LI class="toclevel-3 tocsection-5"><A href="#Safety"><SPAN class="tocnumber">1.3.1</SPAN><SPAN class="toctext">Safety</SPAN></A></LI></UL></TD></TR></TBODY></TABLE><H1><SPAN class="mw-headline" id="Safety_of_medical_application:_A_brief_literature_study"> Safety of medical application: A brief literature study </SPAN></H1><H2><SPAN class="mw-headline" id="VLPs_in_the_human_body"> VLPs in the human body </SPAN></H2><P>Virus-Like Particles have been successfully used in human therapy, both as vaccines and as medical delivery vessels [1-4]. However, adverse effects such as flu-like symptoms or infusion reactions have also been reported [5].

In our theoretical <A href="/Team:Wageningen_UR/HumanBody#Case_study:_colorectal_cancer" title="Team:Wageningen UR/HumanBody">case-study</A>, we want to use our Hepatitis B VLP. In this year’s review by Yang <I>et. al.</I>, the HepB VLP is described as &quot;efficient and safe&quot; [6]. Although the authors focus on its use in vaccines, they also describe how it could vaccinate for other pathogens than the virus it originates from, suggesting that the immune system could be fooled by this particle.

We think that our PnA System may be able to help prevent immune response problems by covering the particle in a stealth coating such as described by Carlisle <I>et. Al</I>. [7]
</P><H2><SPAN class="mw-headline" id="VLP-encapsulated_medicine"> VLP-encapsulated medicine </SPAN></H2><P>Although the majority of literature on medical applications of VLPs focusses on their use as vaccines [1, 2, 8], there are also examples of studies with VLP-encapsulated medicine in humans [3, 4].

In our <A href="/Team:Wageningen_UR/HumanBody#Case_study:_colorectal_cancer" title="Team:Wageningen UR/HumanBody">case-study</A>, we focus on treatment of human colon cancer. Already in 2007, Ramqvist <I>et. al.</I> described the possibilities of treating different cancer variants using VLPs [9].  Today, the most mentioned medicines in the treatment of colon cancer are Irinotecan[10], oxaliplatin[11] and capecitabine [12]. We argue that any medicine can be packaged inside a VLP even if only due to assembly in presence of that medicine, and therefore treatment should be feasible.
</P><H2><SPAN class="mw-headline" id="References"> References </SPAN></H2><P>1.	Harro, C.D., et al., <I>Safety and Immunogenicity Trial in Adult Volunteers of a Human Papillomavirus 16 L1 Virus-Like Particle Vaccine</I>. Journal of the National Cancer Institute, 2001. 93(4): p. 284-292.
</P><P>2.	Roy, P. and R. Noad, <I>Virus-like particles as a vaccine delivery system - Myths and facts</I>. Human Vaccines, 2008. 4(1): p. 5-12.
</P><P>3.	Ma, Y., R.J.M. Nolte, and J.J.L.M. Cornelissen, <I>Virus-based nanocarriers for drug delivery</I>. Advanced Drug Delivery Reviews, 2012. 64(9): p. 811-825.
</P><P>4.	Garcea, R.L. and L. Gissmann, <I>Virus-like particles as vaccines and vessels for the delivery of small molecules</I>. Current Opinion in Biotechnology, 2004. 15(6): p. 513-517.
</P><P>5.	Lorence, R.M., et al., <I>Phase 1 Clinical Experience Using Intravenous Administration of PV701, an Oncolytic Newcastle Disease Virus</I>. Current Cancer Drug Targets, 2007. 7(2): p. 157-167.
</P><P>6.	Yang, X.-Y., H. Bo, and Y.-L. Shu, <I>Hepatitis B virus core antigen as a carrier for virus-like partical vaccine: a review</I>. Bing du xue bao = Chinese journal of virology / [bian ji, Bing du xue bao bian ji wei yuan hui], 2012. 28(3): p. 311-6.
</P><P>7.	Carlisle, R.C., et al., <I>Coating of adeno-associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera</I>. The Journal of Gene Medicine, 2008. 10(4): p. 400-411.
</P><P>8.	Roldao, A., et al., <I>Virus-like particles in vaccine development</I>. Expert Review of Vaccines, 2010. 9(10): p. 1149-1176.
</P><P>9.	Ramqvist, T., K. Andreasson, and T. Dalianis, <I>Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer</I>. Expert Opinion on Biological Therapy, 2007. 7(7): p. 997-1007.
</P><P>10.	de Jonge, H., M. Naesens, and D.R. Kuypers, <I>New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation</I>. Ther Drug Monit, 2009. 31(4): p. 416-35.
</P><P>11.	Takimoto, C.H., et al., <I>Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function</I>. Clin Cancer Res, 2007. 13(16): p. 4832-9.
</P><P>12.	Blesch, K.S., et al., <I>Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience</I>. Invest New Drugs, 2003. 21(2): p. 195-223.
</P><H3><SPAN class="mw-headline" id="Safety"> Safety </SPAN></H3><P><A href="/Team:Wageningen_UR/Safety" title="Team:Wageningen UR/Safety">Introduction</A></P><P><A href="/Team:Wageningen_UR/General_safety" title="Team:Wageningen UR/General safety">1. General safety</A></P><P><A href="/Team:Wageningen_UR/Virus-related_issues" title="Team:Wageningen UR/Virus-related issues">2. Virus-related safety</A></P><P><A href="/Team:Wageningen_UR/Regulations" title="Team:Wageningen UR/Regulations">3. Regulations</A></P><P><A href="/Team:Wageningen_UR/Possible_Improvements" title="Team:Wageningen UR/Possible Improvements">4. Suggestions</A></P><P><STRONG class="selflink">5. Safety of application</STRONG></P><DIV class="printfooter">
Retrieved from &quot;<A href="http://2012.igem.org/Team:Wageningen_UR/Application_safety">http://2012.igem.org/Team:Wageningen_UR/Application_safety</A>&quot;</DIV></DIV></DIV><DIV id="footer-box" class="noprint"><DIV id="footer"><UL id="f-list"><LI id="t-recentchanges"><A href="/Special:RecentChanges" title="Recent changes">Recent changes</A></LI><LI id="t-whatlinkshere"><A href="/Special:WhatLinksHere/Team:Wageningen_UR/Application_safety" title="List of all wiki pages that link here [j]" accesskey="j">What links here</A></LI><LI id="t-recentchangeslinked"><A href="/Special:RecentChangesLinked/Team:Wageningen_UR/Application_safety" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</A></LI><LI id="t-specialpages"><A href="/Special:SpecialPages" title="List of all special pages [q]" accesskey="q">Special pages</A></LI><LI><A href="/Special:Preferences">My preferences</A></LI></UL></DIV><DIV id="footer"><UL id="f-list"><LI id="t-print"><A href="/wiki/index.php?title=Team:Wageningen_UR/Application_safety&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</A></LI><LI id="t-permalink"><A href="/wiki/index.php?title=Team:Wageningen_UR/Application_safety&amp;oldid=286134" title="Permanent link to this revision of the page">Permanent link</A></LI><LI id="privacy"><A href="/2012.igem.org:Privacy_policy" title="2012.igem.org:Privacy policy">Privacy policy</A></LI><LI id="disclaimer"><A href="/2012.igem.org:General_disclaimer" title="2012.igem.org:General disclaimer">Disclaimers</A></LI></UL></DIV></DIV></DIV></BODY></HTML>